Results from the phase II DESTINY-PanTumor02 clinical trial suggest T-DXd has therapeutic utility in other advanced HER2+ and potentially HER2-low and HER2-ultralow cancers, including endometrial, cervical, ovarian, and bladder (62). This evidence concerns the gene ERBB2 and cancer.